Hopewell Therapeutics’ CEO on the company’s $25M raise and next-gen LNPs
- blonca9
- Jun 7, 2023
- 1 min read
Updated: Jun 15, 2023
Lou Brenner discusses his company’s raise today and explains how Hopewell is designing LNPs to go beyond the liver.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
bottom of page